Clinical Trials

184 enrolled

Breast Neoplasms

NCT06875128 2026-03-13

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease

90 enrolled

Phase 2 Active not recruiting

Breast Neoplasms

NCT05810870 2026-03-10

SABINA

14 enrolled

Phase 2 Active not recruiting

Breast Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

24 enrolled

Breast Neoplasms

NCT04986579 2025-11-19

Scalp Cooling in MBC

120 enrolled

Breast Neoplasms

NCT05570253 2025-10-27

A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer

55 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02061085 2025-06-08

MERIBEL

53 enrolled 11 charts

Breast Neoplasms, Ketosis, Neoplasm Metastasis

NCT03222856 2025-06-05

KELLY

44 enrolled 17 charts

Phase 2 Active not recruiting

Breast Neoplasms

NCT02299999 2025-01-15

SAFIR02_Breast

1,460 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT06731153 2024-12-12

JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC

40 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06678230 2024-11-07

Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer

40 enrolled

Breast Neoplasms

NCT01827787 2024-11-06

Eribulin in HER2 Negative Metastatic BrCa

83 enrolled 18 charts

Breast Neoplasms

NCT02681523 2024-09-19

ALERT

8 enrolled 20 charts

Phase 2 Not yet recruiting

Breast Neoplasms

NCT06539559 2024-08-06

Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer

60 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT02035813 2024-06-04

DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).

116 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms, Neoplastic Cells, Circulating

NCT06308939 2024-03-13

Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial

81 enrolled

Breast Neoplasms

NCT00879086 2023-06-22

A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer

104 enrolled 16 charts

Breast Neoplasms, Neoplasms

NCT01268150 2023-06-22

A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer

56 enrolled 10 charts

Breast Neoplasms

NCT01269346 2023-06-22

Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer

52 enrolled 9 charts

Breast Neoplasms

NCT01439282 2023-06-22

Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer

77 enrolled 9 charts

Breast Neoplasms

NCT05833919 2023-04-27

Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients

122 enrolled

Breast Neoplasms

NCT04303741 2023-04-12

A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC

46 enrolled

Breast Neoplasms

NCT05206656 2022-11-23

Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer

80 enrolled

Breast Neoplasms

NCT02000596 2022-05-27

1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.

2 enrolled 7 charts

Breast Neoplasms

NCT01705691 2021-10-06

Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer

50 enrolled 14 charts

Breast Neoplasms

NCT02404506 2021-09-29

Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer

78 enrolled

Adenocarcinoma, Breast Neoplasms

NCT01593020 2021-09-22

Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2

54 enrolled 10 charts

Breast Neoplasms

NCT03795012 2021-08-31

Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients

22 enrolled

Breast Neoplasms, Neoplasm Metastasis, Recurrence

NCT04681911 2020-12-23

Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer

71 enrolled

Breast Neoplasms

NCT04517292 2020-08-18

GEP

160 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02581839 2020-07-30

Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate

9 enrolled 14 charts

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT01908101 2020-07-23

Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer

86 enrolled 10 charts

Breast Neoplasms

NCT02263495 2020-07-14

EG_PG

118 enrolled

Breast Neoplasms

NCT03637868 2020-05-06

ERIBRAIN

Phase 2 Withdrawn

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT01328249 2019-08-20

Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer

81 enrolled 9 charts

Breast Neoplasms

NCT01372579 2019-06-07

Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients

30 enrolled

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT01912963 2018-12-05

Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer

32 enrolled 15 charts

Breast Neoplasms

NCT02481050 2018-11-15

Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer

58 enrolled 14 charts

Breast Neoplasms

NCT01401959 2018-06-15

Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy

127 enrolled 11 charts

Breast Neoplasms, Neoplasm, Residual

NCT03412955 2018-02-27

A Pilot Study of Eribulin in Breast Cancer (BC) Patients With Brain Metastases Previously Treated With Anthracyclines and Taxanes

14 enrolled

Breast Neoplasms

NCT01669252 2017-11-06

NeoEribulin

163 enrolled

Breast Neoplasms

NCT03032614 2017-10-10

Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients

Phase 2 Withdrawn

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT01527487 2016-11-04

Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer

76 enrolled 8 charts

Breast Neoplasms

NCT01498588 2016-10-03

Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer

7 enrolled 7 charts

Breast Neoplasms

NCT02175446 2016-06-15

GIM11-BERGI

61 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT02215876 2016-04-15

Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms

NCT01941407 2016-03-17

ESMERALDA

61 enrolled

Breast Neoplasms

NCT00246090 2014-07-14

A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine

298 enrolled 8 charts

Breast Neoplasms

NCT00965523 2013-08-15

Study of E7389 for Advanced or Metastatic Breast Cancer

81 enrolled 7 charts

Breast Neoplasms, Neoplasms

NCT00097721 2013-04-22

A Study of E7389 in Advanced/Metastatic Breast Cancer Patients

104 enrolled 12 charts